Bg pattern

MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

0.0 (11)
Doctor

Rita Isabel Calero Garcia

General medicine 2 years exp.

Dr. Rita Isabel Calero Garcia is a physician with extensive experience in emergency medical care, general medicine, and healthcare assistance in various clinical and out-of-hospital settings.

She currently works as a physician at the Canary Islands Emergency Service (Servicio de Urgencias Canario – SUC), where she is responsible for the assessment and care of patients in medical emergency situations, performing the initial diagnosis, patient stabilization, and coordination with hospital services when necessary.

She has also developed her professional activity within the Primary Care Management Service, providing consultations in general medicine. In this setting she is responsible for patient follow-up, management of acute and chronic conditions, as well as health promotion and disease prevention.

She has also worked as a physician in a mobile ICU unit, providing medical assistance in out-of-hospital emergencies, treating critical patients and participating in medicalized patient transport.

In addition, she has collaborated with the Red Cross, participating in healthcare support units, providing medical assistance at events and supporting emergency interventions.

Furthermore, she has provided medical services in the private sector with Salvaser, conducting clinical assessments of patients and providing healthcare services within private medical services.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show translation

Introducción

Prospecto: información para el usuario

Miglustat Gen.Orph 100 mg cápsulas duras EFG

miglustat

Lea todo el prospecto detenidamente antes de empezar a tomar este medicamento, porque contiene información importante para usted.

  • Conserve este prospecto, ya que puede tener que volver a leerlo.
  • Si tiene alguna duda, consulte a su médico o farmacéutico.
  • Este medicamento se le ha recetado solamente a usted y no debe dárselo a otras personas aunque tengan los mismos síntomas que usted, ya que puede perjudicarles.
  • Si experimenta efectos adversos, consulte a su médico o farmacéutico, incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver sección 4.

Contenido del prospecto:

  1. Qué es Miglustat Gen.Orph y para qué se utiliza.
  2. Qué necesita saber antes de empezar a tomar Miglustat Gen.Orph.
  3. Cómo tomar Miglustat Gen.Orph.
  4. Posibles efectos adversos.
  5. Conservación de Miglustat Gen.Orph.
  6. Contenido del envase e información adicional.

1. Qué es Miglustat Gen.Orph y para qué se utiliza

Miglustat Gen.Orph contiene la sustancia activa miglustat que pertenece a un grupo de medicamentos que tienen efecto sobre el metabolismo. Se usa para tratar dos transtornos:

  • Miglustat Gen.Orph se usa para tratar la enfermedad de Gaucher tipo 1 leve-moderada en adultos.

En la enfermedad de Gaucher tipo 1, su cuerpo no puede eliminar una sustancia denominada glucosilceramida. Debido a ello se acumula en algunas células de su sistema inmunitario. Esto puede dar lugar a que le aumente de tamaño el hígado y al bazo, se produzcan cambios en la sangre y le afecte a los huesos.

El tratamiento habitual para la enfermedad de Gaucher tipo 1 consiste en la terapia enzimática de sustitución (TES). Miglustat Gen.Orph sólo se utilizará en aquellos casos en los que se considere que la terapia enzimática de sustitución no es adecuada para el paciente.

  • Miglustat Gen.Orph también se usa para el tratamiento de los síntomas neurológicos progresivos de la enfermedad de Niemann-Pick C en adultos y en niños.

Si usted tiene la enfermedad de Niemann-Pick C, pueden acumularse en las células de su cerebro lípidos como la glucosilceramida. Esto puede conllevar una alteración de las funciones neurológicas como lentitud de los movimientos oculares, el equilibrio, la deglución, la memoria o las convulsiones.

Miglustat Gen.Orph actúa inhibiendo la enzima denominada glucosilceramida sintetasa, responsable del primer paso en la síntesis de la mayoría de glucoesfingolípidos.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. Qué necesita saber antes de empezar a tomar Miglustat Gen.Orph

No tome Miglustat Gen.Orph

  • si es alérgico al miglustat o a cualquiera de los demás componentes de este medicamento (incluidos en la sección 6).

Advertencias y precauciones

Consulte a su médico o farmacéutico antes de empezar a tomar Miglustat Gen.Orph

  • si padece enfermedad renal
  • si padece enfermedad hepática

Su médico realizará las siguientes pruebas antes y durante su tratamiento con Miglustat Gen.Orph:

  • exploración física de los nervios de los brazos y piernas
  • medición de los niveles de vitamina B12
  • Monitorización del crecimiento en niños o adolescentes con enfermedad de Niemann-Pick C
  • Monitorización del recuento de plaquetas en sangre

Estas pruebas son necesarias debido a que algunos pacientes han comunicado síntomas como hormigueo o entumecimiento en manos y pies, o una reducción del peso corporal durante el tratamiento con Miglustat Gen.Orph. Las pruebas ayudarán al médico a determinar si estos efectos se deben a su enfermedad o a condiciones ya existentes o son efectos adversos de Miglustat Gen.Orph (ver sección 4 para más detalles).

Si usted padece diarrea, su médico puede solicitarle que modifique su dieta para reducir la ingesta de lactosa e hidratos de carbono tales como la sacarosa (azúcar de caña), o no tomar Miglustat Gen.Orph junto con los alimentos, o reducir temporalmente la dosis. En algunos casos el médico puede recetarle medicamentos para tratar la diarrea, como la loperamida. Consulte a su médico si la diarrea no responde a estas medidas o si presenta cualquier otra molestia abdominal. En dicho caso, su médico puede decidir realizar exploraciones adicionales.

Se aconseja a los pacientes varones que empleen métodos anticonceptivos fiables durante el tratamiento con Miglustat Gen.Orph y hasta tres meses después de finalizar el mismo.

Niños y adolescentes

No administre este medicamento a niños y adolescentes (menores de 18 años de edad) con enfermedad de Gaucher tipo1 porque se desconoce si funciona en esta enfermedad.

Uso de Miglustat Gen.Orph con otros medicamentos

Informe a su médico o farmacéutico si está tomando o ha tomado recientemente o podría tener que tomar cualquier otro medicamento.

Informe a su médico if está tomando medicamentos que contienen imiglucerasa, que a veces se utilizan al mismo tiempo que Miglustat Gen.Orph. Pueden disminuir la cantidad de Miglustat Gen.Orph en su cuerpo.

Embarazo, lactancia y fertilidad

No tome Miglustat Gen.Orph si está embarazada o tiene intención de quedarse embarazada. Para más información, consulte con su médico o farmacéutico. Deberá emplear un método anticonceptivo eficaz mientras esté tomando Miglustat Gen.Orph. No debe proseguir con la lactancia mientras tome Miglustat Gen.Orph.

Los pacientes varones deberán utilizar un método anticonceptivo fiable durante el tratamiento con Miglustat Gen.Orph, y durante los tres meses siguientes tras finalizar el tratamiento.

Si está embarazada o en periodo de lactancia, cree que podría estar embarazada o tiene intención de quedarse embarazada, consulte a su médico o farmacéutico antes de utilizar este medicamento.

Conducción y uso de máquinas

Miglustat Gen.Orph puede producirle mareos. No conduzca ni maneje herramientas o máquinas si se siente mareado.

3. Cómo tomar Miglustat Gen.Orph

Siga exactamente las instrucciones de administración de este medicamento indicadas por su médico.

En caso de duda, consulte de nuevo a su médico o farmacéutico.

  • Para la enfermedad de Gaucher tipo 1:En adultos, la dosis normal es de una cápsula (100 mg) tres veces al día (mañana, tarde, noche), lo cual supone una dosis máxima diaria de tres cápsulas (300 mg).

Para la enfermedad de Niemann-Pick C:En adultos y adolescentes (mayores de 12 años), la dosis normal es 2 cápsulas (200 mg) tres veces al día (mañana, tarde y noche). Esto supone un máximo diario de seis cápsulas (600 mg).

Para niños de menos de 12 años, su médico ajustará la dosis para la enfermedad de Niemann-Pick C.

En el caso de problemas de riñón, su médico puede indicarle una dosis inicial inferior. Es posible que su médico reduzca la dosis de Miglustat Gen.Orph a una cápsula (100 mg) una o dos veces al día en el caso de que se presente diarrea durante el tratamiento con Miglustat Gen.Orph (ver sección 4). Su médico le indicará la duración del tratamiento.

Miglustat Gen.Orph puede tomarse con o sin alimentos. Debe tragarse la cápsula entera con un vaso de agua.

Si toma más Miglustat Gen.Orph del que debe

Si usted toma más cápsulas de las que se le indicó, consulte a su médico inmediatamente. En ensayos clínicos se ha empleado miglustat a dosis diez veces superiores a la dosis recomendada: esto causó una reducción de los leucocitos sanguíneos y otros efectos adversos similares a los descritos en la sección 4.

Si olvidó tomar Miglustat Gen.Orph

Tome la siguiente cápsula cuando corresponda. No tome una dosis doble para compensar las dosis olvidadas.

Si interrumpe el tratamiento con Miglustat Gen.Orph

No interrumpa el tratamiento con Miglustat Gen.Orph sin consultar con su médico.

Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte a su médico o farmacéutico.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Posibles efectos adversos

Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran.

Efectos adversos más graves:

Algunos pacientes han presentado hormigueo o entumecimiento de las manos y los pies (se observa con frecuencia).Estos podrían ser signos de neuropatía periférica, debida a efectos adversos de Miglustat Gen.Orph o podrían ser debidos a enfermedades ya existentes. Su médico realizará pruebas antes y durante el tratamiento con Miglustat Gen.Orph para evaluar su caso (ver sección 2).

Si presenta alguno de estos efectos, comuníquelo a su médico lo antes posible.

Si usted experimentaun ligero temblor, habitualmente temblor en las manos, informea su médico lo antes posible. Con frecuencia el temblor se resuelve sin necesidad de interrumpir el tratamiento. En ocasiones su médico necesitará disminuir la dosis e incluso interrumpir el tratamiento con Miglustat Gen.Orph para controlar el temblor.

Muy frecuentespueden afectar a más de 1 de cada 10 pacientes

Entre los efectos adversos más frecuentes se encuentran diarrea, flatulencia (gases), dolor abdominal (de estómago), pérdida de peso y disminución del apetito.

Si pierde algo de pesoal iniciar el tratamiento con Miglustat Gen.Orph, no se preocupe, por lo general la gente deja de perder peso con la continuación del tratamiento.

Frecuentespueden afectar hasta 1 de cada 10 pacientes

Los efectos adversos frecuentes son dolor de cabeza, mareos, parestesias (hormigueo o entumecimiento), alteraciones de la coordinación, hipoestesias (sensación reducida al tacto), dispepsia (acidez), nauseas (sentirse mareado), estreñimiento y vómitos, hinchazón o molestia del abdomen (estómago) y trombocitopenia (disminución de los niveles sanguíneos de plaquetas). Los síntomas neurológicos y la trombocitopenia pueden deberse a la enfermedad subyacente.

Otros posibles efectos adversosson espasmos musculares o debilidad, fatiga, escalofríos y sensación de malestar, dificultad para dormir, olvidos y disminución de la libido.

La mayoría de los pacientes notan uno o más efectos adversos de este tipo, normalmente al iniciar el tratamiento o en distintos momentos durante el mismo. La mayoría son leves y se resuelven con bastante rapidez. Si alguno de estos efectos adversos le causa problemas consulte con su médico. Él o ella puede que reduzca la dosis de Miglustat Gen.Orph o le recete otros medicamentos para controlar los efectos adversos.

Comunicación de efectos adversos

Si experimenta efectos adversos, consulte a su médico o farmacéutico, incluso si se trata de efectos adversos que no aparecen en este prospecto. También puede comunicarlos directamente a través del sistema nacional de notificación incluido en el Apéndice V. Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento.

5. Conservación de Miglustat Gen.Orph

Mantener este medicamento fuera de la vista y del alcance de los niños.

No utilice este medicamento después de la fecha de caducidad que aparece en el envase después de “CAD”. La fecha de caducidad es el último día del mes que se indica.

Este medicamento no requiere condiciones especiales de conservación.

Los medicamentos no se deben tirar por los desagües ni a la basura. Pregunte a su farmacéutico cómo deshacerse de los envases y de los medicamentos que ya no usa. De esta forma ayudará a proteger el medio ambiente

6. Contenido del envase e información

Composición de Miglustat Gen.Orph

El principio activoes miglustat 100 mg.

Los demás componentes sonalmidón glicolato sódico (tipo A),

povidona (K30)

estearato magnésico

gelatina,

dióxido de titanio

Aspecto del producto y contenido del envase

Miglustat Gen.Orph 100 mg cápsulas duras son cápsulas de gelatina dura de color blanco, con la tapa y el cuerpo opacos, de tamaño 4 y unos 14,0 mm de longitud.

Caja con 12 blísters, conteniendo cada blíster 7 cápsulas, siendo el total de 84 cápsulas.

Titular de la autorización de comercialización:

Gen.Orph

185 Bureaux de la Colline

92213 Saint Cloud Cedex

Francia

Fabricante:

Delpharm Reims

10 rue Colonel Charbonneaux

51100 Reims

Francia

Pueden solicitar más información respecto a este medicamento dirigiéndose al representante local del titular de la autorización de comercialización.

België/Belgique/Belgien

Gen.Orph

Tél/Tel: +33 (0)1 47 71 04 50

e-mail :

[email protected]

Lietuva

Gen.Orph

Tel: +33 (0)1 47 71 04 50

e-mail: [email protected]

????????

????????? ????

???.: +359 2 807 50 00

?-mail: [email protected]

Luxembourg/Luxemburg

Gen.Orph

Tél/Tel.: +33 (0)1 47 71 04 50

email: [email protected]

Ceská republika

Gen.Orph

Tel: +33 (0)1 47 71 04 50

e-mail: [email protected]

Magyarország

Gen.Orph

Tel.: +33 (0)1 47 71 04 50

e-mail: [email protected]

Danmark

Gen.Orph

Tlf: +46 (0)8 21 54 45

e-mail:

[email protected]

Malta

Gen.Orph

Tel: +33 (0)1 47 71 04 50

e-mail : [email protected]

Deutschland

Gen.Orph

Tel: +49 30 8560687897

email:

[email protected]

Nederland

Gen.Orph

Tel: +33 (0)1 47 71 04 50

e-mail: [email protected]

Eesti

Gen.Orph

Tel: +33 (0)1 47 71 04 50

email: [email protected]

Norge

Gen.Orph

Tlf: +46 (0)8 21 54 45

e-mail:

[email protected]

Ελλ?δα

Gen.Orph

Τηλ: +33 (0)1 47 71 04 50

email: [email protected]

Österreich

Gen.Orph

Tel : +33 (0)1 47 71 04 50

e-mail: [email protected]

España

Pharma International S.A.

Tel: +34 915 635 856

e-mail: [email protected]

Polska

Gen.Orph

Tel.: +33 (0)1 47 71 04 50

e-mail: [email protected]

France

Gen.Orph

Tél.: +33 (0)1 47 71 04 50

e-mail: [email protected]

Portugal

PharSolution Pharmaceutical Consulting, Lda.

Tel: +351 21 464 32 25

e-mail: [email protected]

Hrvatska

Gen.Orph

Tel: +33 (0)1 47 71 04 50

e-mail: [email protected]

România

Gen.Orph

Tel: +33 (0)1 47 71 04 50

e-mail: [email protected]

Ireland

Gen.Orph

Tel : +33 (0)1 47 71 04 50

email: [email protected]

Slovenija

Gen.Orph

Tel: +33 (0)1 47 71 04 50

email: [email protected]

Ísland

Gen.Orph

Sími: +33 (0)1 47 71 04 50

e-mail: [email protected]

Slovenská republika

Gen.Orph

Tel: +33 (0)1 47 71 04 50

e-mail: [email protected]

Italia

Biovalley Investments Partner S.r.l.

Tel: +39 040 899 2219

e.mail: [email protected]

Suomi/Finland

Gen.Orph

Puh/Tel :

+46 (0)8 21 54 45

e-mail : [email protected]

Κ?προς

Gen.Orph

Τηλ : +33 (0)1 47 71 04 50

email: [email protected]

Sverige

Gen.Orph

Tel: +46 (0)8 21 54 45

e-mail : [email protected]

Latvija

Gen.Orph

Tel: +33 (0)1 47 71 04 50

e-mail : [email protected]

United Kingdom

Gen.Orph

Tel: +33 (0)1 47 71 04 50

e-mail: [email protected]

Fecha de la última revisión de este prospecto: {mes AAAA}.

La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos: http://www.ema.europa.eu. También existen enlaces a otras páginas web sobre enfermedades raras y medicamentos huérfanos.

Online doctors for MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES

Discuss questions about MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (11)
Doctor

Rita Isabel Calero Garcia

General medicine 2 years exp.

Dr. Rita Isabel Calero Garcia is a physician with extensive experience in emergency medical care, general medicine, and healthcare assistance in various clinical and out-of-hospital settings.

She currently works as a physician at the Canary Islands Emergency Service (Servicio de Urgencias Canario – SUC), where she is responsible for the assessment and care of patients in medical emergency situations, performing the initial diagnosis, patient stabilization, and coordination with hospital services when necessary.

She has also developed her professional activity within the Primary Care Management Service, providing consultations in general medicine. In this setting she is responsible for patient follow-up, management of acute and chronic conditions, as well as health promotion and disease prevention.

She has also worked as a physician in a mobile ICU unit, providing medical assistance in out-of-hospital emergencies, treating critical patients and participating in medicalized patient transport.

In addition, she has collaborated with the Red Cross, participating in healthcare support units, providing medical assistance at events and supporting emergency interventions.

Furthermore, she has provided medical services in the private sector with Salvaser, conducting clinical assessments of patients and providing healthcare services within private medical services.

5.0 (90)
Doctor

Jorge Correa Bellido

General medicine 7 years exp.

Dr. Jorge Correa Bellido is a Spanish physician who offers online consultations in Spanish and English. He graduated from the University of La Laguna and has a solid background in clinical practice and international research.

Throughout his career, he has participated in various medical and academic projects, including a research fellowship in Spain, where he contributed to evidence-based studies in the field of family medicine. This experience allowed him to broaden his global perspective on healthcare and comprehensive patient care.

Dr. Correa Bellido has worked with several healthcare providers in Spain, focusing particularly on patient-centered care and public health initiatives aimed at communities with limited access to healthcare services.

In addition, he actively participates in international medical conferences and workshops, which allows him to stay up to date with the latest medical advances and collaborate with healthcare professionals from different countries.

Dr. Correa Bellido provides comprehensive care for a wide variety of medical conditions, including:

  • respiratory infections
  • gastrointestinal disorders
  • cardiovascular problems
  • endocrine and metabolic diseases
  • musculoskeletal and dermatological conditions
  • as well as mental health conditions such as anxiety and depression.

He also treats infectious and allergic diseases, general health concerns, and provides guidance on prevention and healthy lifestyle habits.

His services include virtual consultations, diagnosis and management of acute and chronic diseases, prescription renewals, and personalized medical advice.

With a patient-centered approach and a strong commitment to continuous learning, Dr. Correa Bellido provides accessible and high-quality healthcare to patients both in Spain and around the world.

0.0 (0)
Doctor

Joao Silva

General medicine 6 years exp.

Dr. João Silva is a physician with training and experience in the field of General and Family Medicine, dedicated to providing healthcare focused on the well-being and quality of life of his patients. Throughout his professional career, he has developed broad clinical competencies, striving to maintain a medical practice based on scientific evidence and continuous knowledge updates.

Between 2013 and 2019, he completed the Integrated Master's Degree in Medicine at the Abel Salazar Institute of Biomedical Sciences in Porto, where he acquired a solid academic and clinical education.

Subsequently, between January 2021 and December 2021, he completed the General Internship at the Entre Douro e Vouga Hospital Center in Santa Maria da Feira, where he had the opportunity to work in different hospital settings and deepen his competencies in several areas of medicine.

From January 2022 until March 2026, he works as a Resident Physician in General and Family Medicine at USF Salvador Machado in Oliveira de Azeméis, developing clinical activities in primary healthcare, follow-up of chronic patients, and health promotion in the community.

Complementing his medical training, Dr. João Silva also completed a Postgraduate Degree in Continuing and Palliative Care at CESPU, strengthening his preparation in the comprehensive approach to patient care, especially in situations requiring prolonged care and multidisciplinary support.

0.0 (17)
Doctor

Daniel Cichi

Family medicine 24 years exp.

Dr Daniel Cichi is a family medicine doctor with over 20 years of clinical experience. He provides online consultations for adults, supporting patients with acute symptoms, chronic conditions, and everyday health concerns that require timely medical guidance. His background includes work in emergency care, ambulance services, and family medicine, which allows him to assess symptoms quickly, identify warning signs, and help patients choose the safest next steps – whether that means home care, treatment adjustment, or in-person evaluation. Patients commonly consult Dr Daniel Cichi for: 

  • acute symptoms: fever, infections, flu-like illness, cough, sore throat, shortness of breath;
  • chest discomfort, palpitations, dizziness, fatigue, and blood pressure concerns;
  • digestive problems: abdominal pain, nausea, diarrhoea, constipation, reflux;
  • sexually transmitted infections, erectile dysfunction;
  • muscle, joint, and back pain, minor injuries, post-traumatic symptoms;
  • chronic conditions: hypertension, diabetes, high cholesterol, thyroid disorders, weight loss, hair loss;
  • review and interpretation of lab tests, imaging reports, and medical documents;
  • medication review and treatment adjustment;
  • medical advice while travelling or living abroad;
  • second opinions and guidance on whether in-person care is needed.

Dr Cichi’s consultations are structured and practical. He focuses on clear explanations, risk assessment, and actionable recommendations, helping patients understand their symptoms and make informed decisions about their health.

5.0 (100)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

0.0 (0)
Doctor

Chikeluo Okeke

General medicine 4 years exp.

Dr Chikeluo Okeke is an internal medicine doctor with extensive international clinical experience. Originally from Nigeria, he has worked across multiple European healthcare systems and currently practises in Sweden. This professional path has given him a strong understanding of different medical approaches and the ability to work effectively with patients from diverse cultural and linguistic backgrounds.

Dr Okeke focuses on general internal medicine and adult primary care, combining clinical accuracy with careful attention to lifestyle, personal context, and everyday health concerns. His consultations are particularly well suited for people who seek medical advice online, live abroad, or need clear guidance without unnecessary complexity.

He provides online consultations covering symptom assessment, prevention, and long-term management of chronic conditions, helping patients understand what is happening and decide on appropriate next steps.

Common reasons for consultation:

  • General internal medicine concerns and initial health assessment.
  • Acute symptoms such as fever, cough, infections, pain, or weakness.
  • Chronic conditions and treatment adjustment.
  • Blood pressure issues, fatigue, metabolic concerns.
  • Preventive consultations and routine check-ups.
  • Interpretation of laboratory results and medical reports.
  • Medical advice for patients receiving care online.

Dr Okeke is known for his clear communication, calm approach, and cultural awareness. He listens carefully, explains medical decisions in a structured way, and supports patients in making informed choices about their health.

Online consultations with Dr Chikeluo Okeke offer reliable internal medicine care without geographic limitations, focused on medical relevance, clarity, and patient comfort.

5.0 (191)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Get MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES Prescription Online

1

Fill in a 2-min form

Tell us your symptoms, history, and what medicine you're requesting.

2

Pick a doctor or let us assign

Choose a specialist or we'll match you with the next available doctor.

3

Doctor reviews your case

Usually within 30 minutes. They may ask follow-up questions via chat.

4

Collect from any pharmacy

Electronic prescription sent to your email — valid across Spain.

Frequently Asked Questions

Is a prescription required for MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES?

MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.

What is the active substance in MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES?

The active ingredient in MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES is miglustat. This information helps identify medicines with the same composition but different brand names.

Who manufactures MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES?

MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES is manufactured by Gen.Orph S.A.S.. Pharmacy brands and packaging may differ depending on the distributor.

Which doctors can assess the use of MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES online?

Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.

How to buy MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES in Spain?

Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.

You can buy MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.

To obtain a prescription, you can use Oladoctor:

What are the alternatives to MIGLUSTAT GEN.ORPH 100 mg HARD CAPSULES?

Other medicines with the same active substance (miglustat) include MIGLUSTAT ACCORD 100 mg HARD CAPSULES, MIGLUSTAT DIPHARMA 100 mg HARD CAPSULES, OPFOLDA 65 mg HARD CAPSULES. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.

bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media